From Casetext: Smarter Legal Research

Mora v. AngioDynamics, Inc.

United States District Court, Southern District of Texas
Nov 1, 2022
Civil Action 1:21-cv-00199 (S.D. Tex. Nov. 1, 2022)

Opinion

Civil Action 1:21-cv-00199

11-01-2022

CELA MORA, “Plaintiff”, v. ANGIODYNAMICS, INC. ET AL., “Defendants”.


ORDER ADOPTING MAGISTRATE JUDGE'S REPORT AND RECOMMENDATION

ROLAND OLVERA, UNITED STATES DISTRICT JUDGE

Before the Court are these pleadings: Defendants' “Motion to Dismiss for Failure to State a Claim” (“MTD”) (Dkt. No. 17), Plaintiffs “Response in Opposition to Motion to Dismiss for Failure to State a Claim” (“Response”) (Dkt. No. 19), Defendants' “Reply in Support of their Motion to Dismiss” (“Reply”) (Dkt. No. 22) and Magistrate Judge's “Report and Recommendation” (“R&R”) (Dkt. No. 34). The R&R recommends this Court (1) grant Defendants' MTD (Dkt. No. 17); (2) dismiss all Plaintiffs claims; (3) deny Plaintiffs request for leave to amend her Complaint; and (4) direct the Clerk of the Court to close this case.

No objections were filed by either party. When no objections are filed to a magistrate judge's ruling, the district court applies the “clearly erroneous, abuse of discretion and contrary to law” standard of review. United States v. Wilson, 864 F.2d 1219,1221 (5th Cir. 1989). Finding no clear error, abuse of discretion, or finding contrary to law, the R&R is ADOPTED.

Defendants' MTD (Dkt. No. 17) is GRANTED. All Plaintiffs claims are DISMISSED. Plaintiffs request for leave to amend her Complaint is DENIED.

The Clerk of the Court is ORDERED to close this case.


Summaries of

Mora v. AngioDynamics, Inc.

United States District Court, Southern District of Texas
Nov 1, 2022
Civil Action 1:21-cv-00199 (S.D. Tex. Nov. 1, 2022)
Case details for

Mora v. AngioDynamics, Inc.

Case Details

Full title:CELA MORA, “Plaintiff”, v. ANGIODYNAMICS, INC. ET AL., “Defendants”.

Court:United States District Court, Southern District of Texas

Date published: Nov 1, 2022

Citations

Civil Action 1:21-cv-00199 (S.D. Tex. Nov. 1, 2022)